Nuvalent Inc. (NASDAQ:NUVL) is one of the best high short interest stocks with huge upside potential. On June 24, Nuvalent ...

New data indicate a targeted drug from Nuvalent could help patients with a rare lung cancer for whom other drugs stopped ...

Brain metastases are common in ROS1-positive NSCLC, particularly after disease progression. Among 56% with measurable brain lesions, zidesamtinib mounted a 48% intracranial ORR, including 20% ...

New study results position Nuvalent to bring forward what it claims is a differentiated treatment for ROS1-positive lung ...

Nuvalent (NASDAQ:NUVL) reported promising results from its mid-stage trial for zidesamtinib, a new drug that specifically ...

Despite a strong cash position and no debt, my NPV model shows NUVB is fairly valued or overvalued at $1.73. Click here to find out why NUVB stock is a Hold.

Leerink raised the firm’s price target on Nuvalent (NUVL) to $140 from $125 and keeps an Outperform rating on the shares.

Cambridge, Massachusetts-based Nuvalent has reported the results of its phase 1/2 ARROS-1 trial of zidesamtinib in previously ...

Company to host webcast and conference call on June 24, 2025 at 8:00am ET CAMBRIDGE, Mass., June 23, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company ...

The NCCN has added taletrectinib to its recommendations for use in all lines of treatments for non–small cell lung cancer ...

ROS1-positive NSCLC is a rare and aggressive form of lung cancer, accounting for approximately 2% of new NSCLC cases, or about 3,000 new diagnoses of advanced disease annually in the U.S.